Please use this identifier to cite or link to this item:
|Title:||Widespread resistance to new antimicrobials in a university hospital before clinical use||Authors:||Kumarasinghe, G.
|Issue Date:||2001||Citation:||Kumarasinghe, G., Chow, C., Tambyah, P.A. (2001). Widespread resistance to new antimicrobials in a university hospital before clinical use. International Journal of Antimicrobial Agents 18 (4) : 391-393. ScholarBank@NUS Repository. https://doi.org/10.1016/S0924-8579(01)00418-6||Abstract:||The activity of cefpirome, cefepime and piperacillin/tazobactam previously unused in the hospital was evaluated in parallel with five broad-spectrum antibiotics (ceftazidime, ceftriaxone, imipenem, ciprofloxacin and amikacin) currently being used to treat serious infections in the National University Hospital, Singapore. Two hundred and two clinically significant, organisms consecutively isolated during 1998 were included in the study. In vitro efficacy of cefepime, cefpirome and piperacillin/tazobactam was not superior to imipenem, ciprofloxacin and amikacin which are currently used. More than 40% of Enterbacteriaceae were found to be ESBL producers. The incidence of nosocomial organisms resistant to drugs used in serious infections had increased since 1995. Imipenem-resistance occurred in 34.4% of Acinetobacter spp. and 19.2% Pseudomonas aeruginosa. No single agent appeared to be suitable for empirical monotherapy of serious sepsis. © 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.||Source Title:||International Journal of Antimicrobial Agents||URI:||http://scholarbank.nus.edu.sg/handle/10635/117966||ISSN:||09248579||DOI:||10.1016/S0924-8579(01)00418-6|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Apr 19, 2021
WEB OF SCIENCETM
checked on Apr 12, 2021
checked on Apr 10, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.